Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1982-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.79.15.4718PMID 6981814PMCID PMC346748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin‐2 Dependent Culture of Cytolytic T Cell Lines

  1981cited by this paper
• Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor.

  1981cited by this paper
• Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

  1981cited by this paper
• Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.

  1980cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis

  1980cited by this paper
• Quantitation and Cloning of Cytolytic T Lymphocytes and their Precursors

  1980cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice

  1980cited by this paper
• Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.

  1979cited by this paper
• Limiting dilution analysis of alloantigen-reactive T lymphocytes. I. Comparison of precursor frequencies for proliferative and cytolytic responses.

  1979cited by this paper
• Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.

  1978cited by this paper
• Stability of transplanted murine tumour systems after storage of cells at -196 degrees C for up to 13 years.

  1978cited by this paper
• Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.

  1977cited by this paper
• A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

  1976cited by this paper
• Induction of immune responsiveness in a genetically low‐responsive tumor‐host combination by chemical modification of the immunogen

  1976cited by this paper
• Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor.

  1975cited by this paper
• Cell‐mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in Murine sarcoma virus (MSV)‐induced tumors and transplanted lymphomas

  1972cited by this paper
• Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus.

  1970cited by this paper
• Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug.

  1970cited by this paper
• Modification in growth of transplantable rat tumors exposed to Friend virus.

  1969cited by this paper
• ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.

  1964cited by this paper
• Immunity to methylcholanthrene-induced sarcomas.

  1957cited by this paper

• CAF-immune cell crosstalk and its impact in immunotherapy

  2022cites this paper
• Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

  2021cites this paper
• Defining Immunogenic and Radioimmunogenic Tumors

  2021cites this paper
• Immune Targets in Colorectal Cancer

  2020cites this paper
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

  2020cites this paper
• Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses

  2018cites this paper
• Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors

  2017cites this paper
• Synergism of co-delivered nanosized antioxidants displayed enhanced anticancer efficacy in human colon cancer cell lines

  2017cites this paper
• Alpha-Enolase (ENO1), a potential target in novel immunotherapies.

  2017cites this paper
• [The interplay of immunotherapy and chemotherapy, a novel approach].

  2016cites this paper
• L’immunothérapie au service de la chimiothérapie, de nouvelles avancées

  2016cites this paper
• Immunogenic cell death.

  2015cites this paper
• Targeted BRAF inhibitors: Immunological effects and combination with immunotherapy

  2015cites this paper
• Apprêtement non conventionnel de peptides antigéniques : production d’antigènes tumoraux par épissage inverse dans le protéasome ou par des protéases distinctes du protéasome

  2015cites this paper
• Eradication of established murine mesothelioma tumours by combined immunotherapy

  2015cites this paper
• Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

  2014cites this paper
• Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses

  2014cites this paper
• Antibody-Redirected T-Cell Immunotherapy for Brain Tumors

  2014cites this paper
• Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers

  2014cites this paper
• Monitoring the immune competence of cancer patients to predict outcome

  2014cites this paper
• Bench-to-bedside challenges in developing immune protection against breast cancer

  2014cites this paper
• Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy

  2014cites this paper
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

  2014cites this paper
• Impact of the immune system and immunotherapy in colorectal cancer.

  2014cites this paper
• The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

  2014cites this paper
• The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.

  2013cites this paper
• Characterisation of high and low avidity peptide specific CD8+ T cells using immunologic, transcriptomic and proteomic tools

  2013cites this paper
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cites this paper
• DNA vaccination against oncoantigens

  2012cites this paper
• Effectiveness and Side-Effects of Slow-Release Systems in CD40 agonistic Antibody Immunotherapy of Cancer. Chapter

  2012cites this paper
• Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism

  2011cites this paper
• Cancer Therapy : Preclinical Local Activation of CD 8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD 40 Antibody

  2011cites this paper
• Sarcoma Immunotherapy

  2011cites this paper
• Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.

  2011cites this paper
• Experimental mouse tumour models: what can be learnt about human cancer immunology?

  2011cites this paper
• A promising cancer vaccine.

  2011cites this paper
• Bispecific antibodies engage T cells for antitumor immunotherapy

  2011cites this paper
• Modulation of T regulatory activity for cancer therapy

  2011cites this paper
• Immunosuppressive myeloid cells under normal and neoplastic conditions

  2011cites this paper
• Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

  2011cites this paper
• Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host

  2010cites this paper
• Mechanisms of T-cell inhibition: implications for cancer immunotherapy

  2010cites this paper
• DENDRITIC CELLS IN A MURINE MODEL OF BREAST CANCER: FUNCTIONAL AND PHENOTYPIC EVALUATION USING NANOPARTICLES

  2010cites this paper
• Early Breast Cancer Patients Prognostic Value for Clinical Outcome of HLA Class I-Negative Tumors Is of HLA-E and HLA-G Expression in Classical

  2010cites this paper
• ANTIBODY ENGINEERING: ADVANCES IN PHAGE DISPLAY TECHNOLOGY AND IN THE PRODUCTION OF THERAPEUTIC IMMUNOCYTOKINES

  2010cites this paper
• The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer

  2010cites this paper
• New data on MAGE-A3 cancer immunotherapy may signal new options for patients with melanoma and non-small cell lung cancer

  2010cites this paper
• HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients

  2010cites this paper
• Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours

  2009cites this paper
• EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma

  2009cites this paper
• Antibody-Based Therapies for Carcinomas

  2009cites this paper
• ProtEx technology for the generation of novel therapeutic cancer vaccines.

  2009cites this paper
• Immunotherapy for HIV-associated non-Hodgkin's lymphoma

  2009cites this paper
• Vers l'utilisation des Immunoglobulines A humaines ou de leurs variants à des fins thérapeutiques

  2009cites this paper
• Lymphocytes genetically modified to express tumor antigens target dendritic cells in vivo and induce antitumor immunity

  2008cites this paper
• Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

  2008cites this paper
• Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?

  2008cites this paper
• Biological Treatment for Liver Tumor and New Potential Biomarkers

  2008cites this paper
• Developing effective tumor vaccines: basis, challenges and perspectives

  2007cites this paper
• Duke University Dissertation Template

  2007cites this paper
• Biologics in Targeted Cancer Therapy

  2007cites this paper
• GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

  2007cites this paper
• Antibody targeted drugs as cancer therapeutics

  2006cites this paper
• Hide and seek: Immune surveillance

  2006cites this paper
• Cytotoxic T cells.

  2006cites this paper
• Immunotherapeutic Approaches for Alzheimer’s Disease

  2006cites this paper
• Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens

  2006cites this paper
• Responses-Dependent Enhancement of Antitumor γ Cyclooxygenase 2 Inhibition Promotes IFN -

  2005cites this paper
• Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.

  2005cites this paper
• T cell activity in glioma chemoresponsiveness and genetics

  2005cites this paper
• Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

  2005cites this paper
• Dendritic cell vaccines and immunity in glioma patients.

  2005cites this paper
• Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus

  2005influential citation
• Transduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity.

  2005cites this paper
• Vaccination and malignant disease: promising therapeutic approach.

  2005cites this paper
• Cyclooxygenase 2 Inhibition Promotes IFN-γ-Dependent Enhancement of Antitumor Responses1

  2005cites this paper
• Immune Cell Subsets Direct or Antagonize Tumor Immunity: Promotion of TH1 Responses in Tumor Vaccination

  2005cites this paper
• Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

  2004cites this paper
• Metastatic phenotype of human prostate tumor cells in athymic nude mice: Alteration by exposure to ethyl methanesulfonate and “reversion” by 5-azacytidine

  2004influential citation
• Biology of the Cancer Vaccine Immune Response

  2004cites this paper
• The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors

  2004cites this paper
• Chemical xenogenization of experimental tumors

  2004cites this paper
• New therapeutic approaches based on gene transfer techniques

  2004cites this paper
• Lung Cancer and Immune Dysfunction

  2004cites this paper
• Immmunotherapy of cancer: from vision to standard clinical practice

  2004cites this paper
• Effective immunotherapy against cancer

  2004cites this paper
• The promise of cancer vaccines

  2004cites this paper
• The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors

  2003cites this paper
• Dendritic cell therapy of cancer: can it fulfill its promise?

  2003cites this paper
• Treatment of Cells with 5-Azacytidine

  2003cites this paper
• Cancer Gene Therapy: Past Achievements and Future Challenges

  2002cites this paper
• Survivin--a universal tumor antigen.

  2002cites this paper
• Review Survivin - a universal tumor antigen

  2002cites this paper
• NO, Immunosuppression and Tumor Immmunotherapy

  2002cites this paper
• Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen

  2002cites this paper
• Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

  2002cites this paper
• Clinical immunotherapy for brain tumors.

  2002cites this paper
• Tumor‐associated antigens identified by mRNA expression profiling induce protective anti‐tumor immunity

  2001cites this paper
• 35 – Approaches to Adoptive Immunotherapy

  2001cites this paper
• Gene-based cancer vaccines: an ex vivo approach

  2001cites this paper